#targeted therapy

What Is Targeted Therapy?

Adding Tukysa to Kadcyla led to an improvement in progression-free survival, including for patients whose cancer had spread to the brain.

Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.

Capivasertib/fulvestrant combo is approved for patients with HR-positive/HER2-negative advanced breast cancer with specific mutations.

Repotrectinib led to tumor shrinkage in 79% of patients who had not previously used a tyrosine kinase inhibitor.

Researchers are investigating AI’s potential to transform cancer care and improve patient outcomes.

The novel treatment is successful for blood cancers, but results in patients with solid tumors have not been nearly as impressive.

Cabometyx improved progression-free survival versus placebo in people with neuroendocrine tumors inside or outside the pancreas.

People who received the targeted therapy after surgery were less likely to experience recurrence or brain metastasis.

Researchers sought to understand both neuroendocrine tumors themselves and the surrounding cells in the tumor microenvironment.

Adding chemotherapy to Tagrisso was associated with a nearly nine-month delay in disease progression—and more side effects.

Because of its rarity, adenoid cystic carcinoma has received relatively little attention from cancer researchers.

Vemurafenib (Zelboraf) and cobimetinib (Cotellic) may substantially delay, or even eliminate, the need for added treatments.

The results were extraordinary, with participants experiencing an average 90% reduction in tumor size.

Talquetamab is indicated for patients who have tried at least four prior lines of treatment.

Ruxolitinib might have contributed to a functional cure after a stem cell transplant without a rare mutation.

Trial showed that treatment with quizartinib led to a significant improvement in overall survival.